Veranova’s subsidiary, Macfarlan Smith announced today the completion of a $10 million expansion of its mid-scale active pharmaceutical ingredient (API) manufacturing capabilities at its Edinburgh, UK facility.

The multi-purpose asset, able to handle highly active APIs and intermediates, is positioned to enable growth in the generic opioid analgesic and anti-addiction markets, while also supporting the growing demands of Veranova’s existing customer base and unlocking future growth.

This expansion is the first of two investments, and the second is currently undergoing commissioning. Once completed, these expansions will represent $17 million of funding.

“This investment will see the Edinburgh facility expand to meet the growing demands that we are witnessing from customers and improve the flexibility of our asset base,” said David Payne, Director of Veranova’s Scotland manufacturing operations.

“The opening of our Edinburgh facility expansion illustrates Veranova’s commitment to the provision of essential medicines, a reliable supplier of controlled substances to our global customer base,” said Niek Stapel, CEO of Veranova.